Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance. - Wikidata - wikimedia - TriplyDB

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance.

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance.

http://www.wikidata.org/entity/Q36085847

about

Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44 Benzyl isothiocyanate induces protective autophagy in human lung cancer cells through an endoplasmic reticulum stress-mediated mechanism.Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles.mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy.Triphenyl Phosphine-Functionalized Chitosan Nanoparticles Enhanced Antitumor Efficiency Through Targeted Delivery of Doxorubicin to Mitochondria.Zinc-Modified Nanotransporter of Doxorubicin for Targeted Prostate Cancer Delivery.Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy.The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery.In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer.

P2860

Q28566589-1723C2DC-0BEE-4850-A176-C596A178C278 Q37744761-9457B1F5-C43D-46FC-9947-A89EACBC3659 Q38937583-7256BC77-3FAB-46AB-9D87-1534BE030057 Q41911833-489BB13F-7C37-4D23-9D1A-341F299832AB Q42255827-0EEBBABD-EBFD-47CE-BB6C-9CB33D6B3231 Q47145371-4663BFDE-9EEE-4835-8905-77AF1FD60BB2 Q47808831-1843A198-C52F-40D8-9127-FCD75AB46067 Q48093677-7C610054-B5BC-46E5-8C80-A8EA57627C13 Q50272082-315B1AD4-39DC-41E5-9E80-33A9CBA382E8

P2860

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance.

http://www.wikidata.org/entity/Q36085847

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Co-delivery of Gefitinib and c ...... the drug acquired resistance.

@ast

Co-delivery of Gefitinib and c ...... the drug acquired resistance.

@en

type

label

Co-delivery of Gefitinib and c ...... the drug acquired resistance.

@ast

Co-delivery of Gefitinib and c ...... the drug acquired resistance.

@en

prefLabel

Co-delivery of Gefitinib and c ...... the drug acquired resistance.

@ast

Co-delivery of Gefitinib and c ...... the drug acquired resistance.

@en

P1433

Q36085847-21A5BAF0-7C43-4B4A-8A95-7474B347FACC

P1476

Q36085847-A3DE32C3-A190-4AB8-B697-DC15B5FF883D

P2093

Q36085847-013D1B29-EC62-4BFA-8DB6-650EBA7714B5

Q36085847-3C397B60-44BD-4839-94DC-33B45DB55386

Q36085847-86292D6E-1B72-4686-A8DE-5E8C07670730

Q36085847-87D81A0D-A7C5-4208-99D5-D57D2C7CC787

Q36085847-B496B596-6E44-48B5-94D6-475AD3062443

P2860

Q36085847-09E30001-4E43-4907-AF50-8D4BC88E7514

Q36085847-117A0D51-E6A1-49C6-B70E-368F0E9F1E7C

Q36085847-1AC00559-1A7B-41A0-AEA3-8F1E77B4C785

Q36085847-2017141D-78C6-4143-BE5E-5F0E78AEB10E

Q36085847-213AA077-8216-4EA4-B2A4-EE2B57C14403

Q36085847-23780C0C-A503-49DE-8C8F-EA2DBC864AF9

Q36085847-29EC2B03-673C-4BA1-BD3E-FD6E368C031E

Q36085847-2E138460-7F1F-4F51-A221-C92B9534328D

Q36085847-3DA4E3B8-EF79-4A8E-B7A2-FDD89988D55D

Q36085847-54FD11DB-D15A-414D-A0FE-FC2EA55FFAEA

P2888

Q36085847-256DBEC0-5C98-42EB-B506-559920B556FB

P304

Q36085847-03368D7E-01B2-48CB-8491-9D77C70FCACA

P31

Q36085847-C952E17B-DB10-4B7D-8844-4363EF3AB7D3

P356

Q36085847-F4A00C37-8949-423D-B917-35AC9AA7302C

P478

Q36085847-D6252BB3-80AE-4126-83F6-3BA8B1BB9954

P577

Q36085847-15E437B8-D6AB-4151-BEFB-AFEFA13BBF73

P5875

Q36085847-53D21A77-241A-4B35-8C56-14C3E922191D

P6179

Q36085847-4481F9DD-1B47-48AD-8355-E65161ADBBDA

P698

Q36085847-34F7DEB4-A15D-4D5C-B3F3-852E92A232C9

P921

Q36085847-0EE8A14D-9996-43CA-9470-4603818C9D85

P932

Q36085847-0B8696A5-8CBB-4AF4-A847-B987932508AB

P356

S12951-015-0121-5

P1433

Journal of Nanobiotechnology

P1476

Co-delivery of Gefitinib and c ...... the drug acquired resistance.

@en

P2093

Chang Su

http://www.w3.org/2001/XMLSchema#string

Guang Yang

http://www.w3.org/2001/XMLSchema#string

Jin Chang

http://www.w3.org/2001/XMLSchema#string

Liang Zhao

http://www.w3.org/2001/XMLSchema#string

Yijie Shi

http://www.w3.org/2001/XMLSchema#string

P2860

A comprehensive glossary of autophagy-related molecules and processes (2nd edition)

Autophagy in lysosomal storage disorders

Development of autophagy inducers in clinical medicine

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heat-labile enterotoxin subunit B mediation.

Nanoparticle delivery of cancer drugs.

Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors

EGFR and cancer prognosis.

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

P2888

s12951-015-0121-5

P304

57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12951-015-0121-5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282129033

http://www.w3.org/2001/XMLSchema#string

P6179

1012728778

http://www.w3.org/2001/XMLSchema#string

P698

26395758

http://www.w3.org/2001/XMLSchema#string

P921

P932

4579980

http://www.w3.org/2001/XMLSchema#string